Researchers are investigating the therapy as a treatment for B-cell malignancies, but they might also investigate as a treatment for multiple sclerosis and lupus.

Authorities have named Mangione, 26, as a person of interest in last week’s fatal shooting of United Healthcare CEO Brian Thompson in Manhattan. He was taken into custody at a McDonald’s in Altoona, Pennsylvania around 9 a.m. ET, officials said.

Beginning in January 2025, Optum Rx will remove from several Humira biosimilars from its formulary, including Hyrimoz (adalimumab-adaz), the unbranded Hyrimoz and Cyltezo (adalimumab-adbm).

The biggest advantage of suzetrigine would be that it helps patients avoid the use of opioids for acute pain. The FDA’s goal date for suzetrigine is Jan. 30, 2025.

Here’s what you missed this week on Managed Healthcare Executive.

CVS Health recently appointed Len Shankman as president of Pharmacy and Consumer Wellness and Lucille Accetta as chief pharmacy officer.

Aerobic exercise, particularly static exercises like yoga and stretching, performed 70 to 90 minutes three times a week over eight to 10 weeks, can significantly improve sleep disorders in menopausal women.

The out-of-pocket cost for MS disease-modifying therapies jump by 217% going from $750 per year in 2012 to $2,378 per year in 2021.

Psilocybin-assisted therapy, which involves using the active ingredient from "magic mushrooms," could benefit roughly 5 million people currently receiving treatment for major depressive disorder and treatment-resistant depression if the FDA approves it.

The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.

Roche’s Evrysdi is the market leader among the drugs for spinal muscular atrophy. Biogen’s Spinraza has struggled, but company officials express confidence about future sales.

On financial toxicity, and when, how and by whom it should be discussed.

Patients and their caregivers might benefit from being aware of the stigma to advocate for compassionate, optimal care.

A systematic review and network meta-analysis examined research on four types of treatment for children with post-traumatic stress disorder. Trauma-focused cognitive behavioral therapy was the clear winner.

10 treatments are listed as first-line advanced therapies. Rinvoq (upadacitinib) is the only one with a clinically meaningful difference from placebo of over 20%.

Patients with type 1 diabetes were more likely to be prescribed continuous glucose monitoring compared with those with type 2 diabetes, a new analysis finds.

In a meta-analysis of 57 studies, Zolgensma achieved a 95% survival rate and reduced the number of patients requiring ventilatory support.

Thompson, who was on his way to attend an annual investor conference in Manhattan today, was shot after 6:45 a.m. in a targeted attack, police officials say.

Effective July 1, 2025, this agreement ensures that nearly 400,000 patients covered by IBX each year will keep receiving quality care from Penn Medicine providers. The partnership focuses on improving health outcomes, patient experiences, and controlling costs, aiming to set new standards for innovative care in healthcare, according to a release.

The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.

The researchers hope their discoveries will lead to novel strategies to not just slow fibrosis but promote functional repair of the injured lung.

The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date has been set for Sept. 26, 2025.

Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated in the pulmonary artery smooth muscle cells of patients.